Repligen Corp. announced Wednesday that the U.S. DistrictCourt for the District of Massachusetts has entered a consentdecree by which Aaston Inc. is prohibited from making, using,selling or importing recombinant Protein A covered byRepligen's U.S. Patent No. 5,151,350.
Repligen of Cambridge, Mass., had filed a lawsuit on June 2charging Aaston with infringement of the patent.
The patent covering Repligen's recombinant protein A (rProteinA) products was issued to Repligen (NASDAQ:RGEN) on Sept. 29,1992. rProtein A is used primarily in antibody purification,diagnostic kits and research applications such as fractionation,immunoprecipitation and radioimmunoprecipitation.
(c) 1997 American Health Consultants. All rights reserved.